Please, Signup (Login) to subscribe or trade (demo)
Pfizer stock price
Pfizer latest news:
U.S. FDA expands approval for Pfizer cancer drug Sutent
The U.S. Food and Drug Administration on Thursday approved the use of Pfizer Inc's (PFE) cancer drug Sutent to help prevent kidney cancer from returning following surgical removal of a kidney. Sutent was approved in 2006 for patients with gastrointestinal stromal tumors and advanced kidney cancer.
UPDATE 1-Pfizer creates chief operating officer role for Bourla
NEW YORK, Nov 13 (Reuters) - Drugmaker Pfizer Inc
has promoted Albert Bourla to the newly created post of chief
operating officer, freeing up Chief Executive Officer Ian Read
to focus more on long-term strategy and engaging with government
and industry leaders.
Dow futures fall as 26 of 30 components trade lower premarket
As the Dow Jones Industrial Average threatens to open with a triple-digit loss, 26 of the 30 components traded lower in premarket trade. Among the biggest decliners, shares of Intel Corp. fell 1.3%, American Express Co. shed 1% and Cisco Systems Inc. fell 0.7%. Among the gainers, shares of both Boeing Co. and Pfizer Inc. edged up 0.3%. Dow futures slumped 92 points ahead of the open.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Pfizer expects broad interest for consumer health business
NEW YORK (Reuters) - Pfizer Inc, the largest U.S. drugmaker, expects no shortage of suitors for its consumer health business and said it would decide whether to sell, spin off or retain the unit next year.
Pfizer beats 3Q net forecasts on lower charges, higher sales
Pfizer doubles 3Q net income due to slightly higher sales and lower charges, tops profit expectations
Pfizer Earnings Not Enough for Investors
Pfizer sets date for auction of consumer healthcare unit: Reuters
Pfizer Inc. will begin the auction process for its consumer healthcare unit in November, which it hopes will end in a $15 billion sale, Reuters reported late Wednesday, citing sources close to the matter. GlaxoSmithKline PLC. and Reckitt Benckiser are among those companies that have said they would consider bidding for the Pfizer unit. One of the sources told Reuters that initial discussions with Reckitt have already happened. Other possible bidders may include Procter & Gamble , Sanofi SA , Johnson & Johnson and Nestle [s:
ch:nesn], sources said. The companies have been contacted for comment.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
UK Stocks-Factors to watch on Oct 26
Oct 26 (Reuters) - Britain's FTSE 100 index is seen opening up 16
points at 7,463.5 on Thursday, according to financial bookmakers.
* GLAXOSMITHKLINE: The committee responsible for U.S. vaccination schedules
has given a preferential recommendation to GlaxoSmithKline's newly
approved shingles vaccine Shingrix over Merck & Co's established product
* GSK/RB: Pfizer to kick off auction process for its consumer
healthcare business in November, paving the way for a potentia
Exclusive: Pfizer to launch consumer health sale in November - sources
Pfizer plans to kick off an auction process for its consumer healthcare business in November, paving the way for a potential $15 billion-plus sale of the headache pill to lip balm business, sources close to the matter told Reuters.
GlaxoSmithKline stock plummets 6% after concerns about dividend risk
GlaxoSmithKline PLC shares plummeted 6% in extremely heavy midday trade Wednesday on concerns that the company's interest in Pfizer Inc.'s over-the-counter business could put its dividend at risk. After being asked if she could give investors assurances that the potential deal would carry no dividend risk, Chief Executive Emma Walmsley did not exactly give those assurances. "We know the dividend matters to our investors. We intend and we do pay it now as a function of our free cash flow after investing in the necessary priorities to secure long-term growth for the company," Walmsley said, according to the FactSet transcript of the company's third-quarter earnings call, adding, "we confirmed our intentions to pay the dividend in 2017 of 80 pence and again in 2018 and then we will be returning to declaring the dividend quarterly and not giving a more specific outlook beyond that." When Walmsley was again pressed about the potential Pfizer deal, she said it was "too premature and hypothetical." "For us, even though we believe pricing (mostly in Respiratory) and competitive concerns (Respiratory and HIV) are largely factored into the stock at current levels, investors remain focused on the safety of the dividend," said Leerink Partners analyst Seamus Fernandez. GlaxoSmithKline shares have dropped 9.5% over the last three months, compared with a 2.9% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Pfizer considers consumer business sale
Pfizer to sell consumer business
Pfizer considers consumer business sale
Pfizer may be done selling ChapStick, Advil, Robitussin and other brands that people can buy without a prescription.
Pfizer weighs $15 billion sale of consumer healthcare business
(Reuters) - Pfizer said on Tuesday it was considering the sale or spin-off of its consumer healthcare business, shaking up the industry and potentially putting a headache pill to lip balm operation worth some $15 billion up for grabs.
UPDATE 4-Pfizer weighs $15 bln sale of consumer healthcare business
* Possible buyers include existing OTC drugmakers and Nestle
(Adds Breakingviews link)
Pfizer mulls sale of consumer business
The company's consumer health business contains brands such as Advil, Robitussin and ChapStick.
Pfizer is mulling sale, spin-off of its consumer health-care business
Pfizer on Tuesday said it is reviewing strategic alternatives for its consumer health-care business.
Versartis shares halted
Shares of Versartis Inc. were halted late Thursday after the biopharmaceutical company said its drug somavaratan failed to meet its primary endpoint in a phase 3 trial. The drug, a form of human growth hormone that seeks to treat growth-hormone deficiency, failed to demonstrate superiority to Genotropin, an offering from Pfizer Inc. , in a study focusing on pediatric growth-hormone deficiency. "We are very surprised and disappointed to learn the outcome," Chief Executive Jay Shepard said in Thursday's announcement, adding that the company planned to provide a corporate update later this year. Versartis shares have gained 27% in the past three months, more than 10 times the gains for the S&P 500 Index in the same period, and nearly 45% so far this year. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Pfizer accuses Johnson & Johnson of 'anticompetitive practices' in lawsuit
Pfizer filed a lawsuit against fellow pharmaceutical giant Johnson & Johnson over "anticompetitive practices" with the drug Remicade.
Pfizer files suit against J&J over Remicade contracts
(Reuters) - Drugmaker Pfizer Inc on Wednesday filed a lawsuit against Johnson & Johnson , saying its rival's contracts with health insurers for blockbuster rheumatoid arthritis drug, Remicade, were anticompetitive and blocked sales of Pfizer's new biosimilar.
United Technologies, Pfizer Lead DJIA Higher on Thursday
Why Pfizer Is Pushing the Dow to All-Time Highs
Pfizer, Astellas prostate cancer drug promising in late-stage trial
* Xtandi meets main goal in late-stage trial. * Analyst says expanded use to double market size. * Pfizer's shares up 1.8 pct. By Divya Grover. Pfizer Inc (PFE) and Japan's Astellas Pharma Inc (ALPMF) said on Thursday their blockbuster prostate cancer drug met the main goal of a key study that tested it for treating the disease in its early stages.
Pfizer, Astellas prostate cancer drug clears late-stage trial
Pfizer Inc(PFE) and Astellas Pharma Inc (ALPMF) said on Thursday their drug to treat a type of prostate cancer met the main goal in a late-stage trial. The drug, Xtandi, in combination with an anti-hormone therapy showed statistically significant improvement in metastasis-free survival rate in men with non-metastatic castration-resistant prostate cancer when compared with the standalone anti-hormone therapy.
FDA warns of serious manufacturing violations in letter to EpiPen manufacturing facility
The Food and Drug Administration described "significant violations of current good manufacturing practice" in a warning letter to a Pfizer unit that manufactures Mylan's EpiPen allergic reaction treatment. The unit, Meridian Medical Technologies Inc., "failed to thoroughly investigate multiple serious component and product failures... including failures associated with patient deaths and severe illness," the warning letter said, referring to an FDA inspection of a Missouri manufacturing facility between February and March of this year. "You also failed to expand the scope of your investigations into these serious and life-threatening failures or take appropriate corrective actions, until FDA's inspection." The regulator asked the company to review its manufacturing investigations and provide its plan for addressing safety risks, all within 15 days. If the company doesn't promptly fix the violations, there may be legal action, and the FDA may not approve applications listing the manufacturing facility, the FDA said. Mylan shares declined nearly 1% in moderate Thursday afternoon trade, while Pfizer shares rose a scant 0.3% in heavy trade, compared with a 0.1% decline in the S&P 500 Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
FDA approves Pfizer's leukemia drug
(Reuters) - The U.S. Food and Drug Administration (FDA) on Friday approved Pfizer Inc's drug, Mylotarg, for certain patients with acute myeloid leukemia (AML).
UPDATE 1-FDA approves Pfizer's leukemia drug
Sept 1 (Reuters) - The U.S. Food and Drug Administration
(FDA) on Friday approved Pfizer Inc's drug, Mylotarg,
for certain patients with acute myeloid leukemia (AML).
BRIEF-Pfizer receives FDA approval for MYLOTARG (gemtuzumab ozogamicin)
* Pfizer receives FDA approval for MYLOTARG (gemtuzumab
Source text for Eikon:
Further company coverage:
DuPont, Pfizer Carry DJIA Higher Thursday
Is the System Rigged Against Biosimilars?
Pfizer and Amgen are encountering problems getting traction for their biosimilars. Is the system rigged against them?
BRIEF-Pfizer and Sangamo updates on early stage trial on its blood disorder therapy
Pfizer Inc(PFE): * Sangamo and Pfizer announce first patient receives treatment in Phase 1/2 clinical trial evaluating SB-525 investigational gene therapy for Hemophilia A Source text for Eikon: Further company coverage:
Philip Morris International IncPM
Philippine Long Distance Telephone CompanyPHI
Phillips 66 Partners LPPSXP
Phoenix New Media LimitedFENG
Physicians Realty TrustDOC